LGD-3303

LGD-3303 is a nonsteroidal selective androgen receptor modulator (SARM) with high oral bioavailability. It acts as a potent and selective agonist of the androgen receptor (Ki = 0.9 nM), showing much lower affinity for mineralocorticoid, glucocorticoid, and progesterone receptors. Functionally, it displays tissue selectivity by acting as a full agonist for anabolic effects (such as muscle growth and bone density) while being only a partial agonist for androgenic effects (such as prostate growth). In animal studies, LGD-3303 increased muscle mass and bone mineral density without significantly stimulating prostate tissue or other unwanted androgenic side effects. It has been investigated primarily for potential treatment of osteoporosis and conditions involving muscle wasting[1][2][4][5][7]. Developers: Ligand Pharmaceuticals

Other names

9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo[3,2-f]quinolin-7(6H)-one